Substitute for form 1449A/PTC

INFORMATION DISCL STATEMENT BY APP

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/774,393			
Filing Date	February 10, 2004			
First Named Inventor	CRIPPS et al.			
Art Unit	1616			
Examiner Name	M. Haghighatian			
Attomey Docket Number	CRIP3001C3/RFF			

Sheet	1 of 1				Attomey	omey Docket Number CRIP3001C3/REF	
			U. S. I	PATENT D	OCUMEN.	TS	
Examiner Cite No. 1 Initials*	Cite No. 1				Publication Date MM-DD-YYYY	Name of Patentee o Applicant of Cited Document	or Pages, Columns, Lines, Where Relevant Passages or
							Relevant Figures Appear
/MH/		US-	5,658,549 A	8/5/19	97	Akerhurst, et al.	
1		US-	5,919,827 A	7/6/19	99	Barberich, et al.	
		US-	6,004,537 A	12/21/	1999	Cavanaugh, et al.	
	1	US-	5,795,594	8/1998	3	York, et al.	
/MH/		US-	5,270,305	12/199		Palmer, et al.	Duplicate
		U0-	4,249,548	11/19		Heeb, et al.	Dupiicace
/MH/		US-	5,776,432	7/7/19	98	Schultz, et al.	
1		US-	6,346,232 B1	2/12/2	002	Schultz, et al.	
		US-	10/130,847	5/21/2	002	Cripps, et al.	
1		US-	6,231,519	5/200		Blunts, et al.	
1	1	US-	6,610,273	8/2003	3	Wu et al.	
/MH/		US-	3,219,533	11/23/	1965	Mullins	

		FOREIGN	PATENT DOCU	MENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Codes -Number 4 -Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Те
/MH/		WO 01/37805 A1	5/31/2001	Glaxo Group Ltd.	Whole document	
/MH/		EP 0 416 951 A	3/13/1991	Glaxo Group Ltd.	Whole document	
		WO 98 56349 A	12/17/1998	Chiesi Farmaceutici SPA	Whole document Duplicate	
/MH/		WO 98 24420 A	6/11/1998	Bioglan Ireland (R&D) Ltd.	Whole document	
/MH/		WO 94 13262	6/23/1994	P. D. Jager, et al.	Whole document	
/MH/		WO 00 30607	6/2/2000	Chiesi Farmaceutici SPA	Whole document	
/MH/		WO 99 65464 A	12/23/1999	Boehringer Ingel Pharm., Inc.	Whole document	
/MH/		CA 2,094,266	4/22/1998	MN. Mining & Manuftg Co.	Whole document	
/MH/		WO 92/06675	4/30/1992	MN. Mining & Manuftg Co.	Whole document	
/MH/		EP 0 553 298 B1	11/17/1994	MN. Mining & Manuftg Co.	Whole document	
/MH/		AU-B-90873/91	5/20/1992	MN. Mining & Manuftg Co.	Whole document	
/MH/		GB 2 235 627 A	3/13/1991	Glaxo Group Ltd.	Whole document	

Examiner Signature	/Mina Haghighatian/	Date Considered	03/15/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Applicant's unique citation designation number (optional).
See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
See Kinds Codes of USPTO Patent Documents, by the two-letter code (WIPO Standard ST.3).
For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible.
Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (09-06)

Substitute for form 144B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

DEC 2.7 2006

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/774,393			
Filing Date	February 10, 2004			
First Named Inventor	CRIPPS, et al.			
Art Unit	1616			
Examiner Name	M Haghighatian			
Attorney Docket Number	CRIP3001C3/REF			

Sheet		1 of	1	Attorney Docket Number	CRIP3001C3/REF	
			NON PATENT LITERATI	URE DOCUMENTS		,
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
/MH/ 		from Pressurize	d Aerosols Formula	on of Output Particle Size ted as Solutions or Suspe bl. 5, no. 1, pp. 36-39	Distributions nsions",	
		S.S. Davis, "Phy I. Water-Propyle 1978, vol. 1, pp.	ene Glycol Systems'	lies on Aerosol Solutions f , International Journal of l	for Drug Delivery Pharmaceutics,	
				rticle size for β -adrenergic f Pharmaceutics, 1994, vo		
		Peter Zanan, et in mild asthmati 111-115	al., "The optimal pa cs", International Jo	rticle size for parasympati urnal of Pharmaceutics, 1	nicolytic aerosols 995, vol. 114, pp.	
/MH/		Peter Zanan, et aerosols in patie 977-980	al., "Optimal particle ents with severe airf	e size for β_2 agonist and a low obstruction", Thorax, $\frac{1}{2}$	nticholinergic 1996, vol. 51, pp.	

Examiner Signature	/Mina Haghighatian/	Date Considered	03/15/2007
-----------------------	---------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.